Panelists analyze comparative real-world data from the French DESCAR-T registry evaluating axicabtageneciloleucel and lisocabtagenemaraleucel in second-line relapsed/refractory LBCL. Faculty consider distinctions in toxicity profiles along with selection bias, vein-to-vein time, patient frailty, and whether certain patients may preferentially benefit from one CAR T product over another in routine second-line practice.
